Research
Search
Close
XU Feng
- Graduate Supervisor, Associate Researcher, Associate Chief Physician
- Department: Hematology
- Research Area: Internal Medicine (Hematology)
- Research Interests: Pathogenesis of myelodysplastic syndromes
- Contact: xvfeng3619@163.com
- Physician, Department of Hematology, Shanghai Sixth People's Hospital, 2013
- PhD from Shanghai Jiao Tong University School of Medicine, 2012
- Joint PhD training at Fred Hutchinson Cancer Research Center, University of Washington, USA, 2011
- MD from Xiangya School of Medicine, Central South University, 2002
- Associate Chief Physician, Department of Hematology, Shanghai Sixth People's Hospital
- Huang N, Song Y, Shi W, Guo J, Zhang Z, He Q, Wu L, Li X, Xu F. DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes. iScience. 2023;26(6):106962.
- Xu F, Wu LY, Guo J, He Q, Zhang Z, Li X. Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes. J Cell Mol Med. 2022;26(23):5901-5916.
- Li X, Xu F, Wu LY, Guo J, He Q, Zhang Z. Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes. J Cell Mol Med. 2022;26(12):3586-3589.
- Li X, Xu F, Zhang Z, Guo J, He Q, Song LX, Wu D, Zhou LY, Su JY, Xiao C, Chang CK, Wu LY. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clin Epigenetics. 2021;13(1):169.
- Li X, Xu F, Wu LY, Zhao YS, Guo J, He Q, Zhang Z, Chang CK, Wu D. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations. Sci Rep. 2020;10(1):826.
- Liu L, Xu F, Chang CK, He Q, Wu LY, Zhang Z, Li X. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21. Cell Death Dis. 2017;8(10):e3126.
- Xu F, Wu LY, He Q, Wu D, Zhang Z, Song LX, Zhao YS, Su JY, Zhou LY, Guo J, Chang CK, Li X. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Sci Rep. 2017;7:43113.
- Xu F, Liu L, Chang CK, He Q, Wu LY, Zhang Z, Shi WH, Guo J, Zhu Y, Zhao YS, Gu SC, Fei CM, Li X. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome. Oncotarget. 2016;7(7):8119-30.
- Xu F, Wu LY, Chang CK, He Q, Zhang Z, Liu L, Shi WH, Guo J, Zhu Y, Zhao YS, Gu SC, Fei CM, Wu D, Zhou LY, Su JY, Song LX, Xiao C, Li X. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nat Commun. 2015;6:8806.
- Xu F, Li X, Wu L, He Q, Zhang Z, Chang C. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol. 2010;149(4):587-97.
